Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | VAXX | Class A common stock | Purchase | $62.5K | +18.1K | +0.04% | $3.45 | 51.6M | Apr 26, 2022 | Direct | F1, F2, F3 |
transaction | VAXX | Class A common stock | Purchase | $17.2K | +4.81K | +0.01% | $3.58 | 51.6M | Apr 27, 2022 | Direct | F1, F2 |
holding | VAXX | Class A common stock | 4.21M | Apr 26, 2022 | Held by United Biomedical Inc., Asia | F4 |
Id | Content |
---|---|
F1 | The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
F2 | The price reported is a weighted average price. |
F3 | This number reflects an update and a correction from Reporting Person's Form 4 filed April 27, 2022, which should have reported that the Reporting Person beneficially owned 51,593,454 shares of Class A common stock instead of 5,193,454 shares of Class A common stock, which was accidentally reported. |
F4 | Held by United Biomedical, Asia Inc. ("UBIA"). The Reporting Person, through a subsidiary, holds a majority equity interest in UBIA and may be deemed to be the beneficial owner of the shares held by UBIA. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by UBIA in which the Reporting Person has no pecuniary interest. |